Objective To describe the maternal and neonatal outcomes and prolongation of pregnancies with severe early onset pre-eclampsia before 26 weeks of gestation.
Introduction
Pre-eclampsia remains a common pregnancy disorder, with high maternal and neonatal mortality and morbidity. It affects 2-5% of pregnancies, 1 and occurs most commonly at term. At extremely premature gestational ages, severe preeclampsia and HELLP (haemolysis, elevated liver enzymes, and low platelets) syndrome are rare. At present, delivery of the fetus is the only curative treatment of hypertensive pregnancy complications, but for women with early pre-eclampsia this inevitably leads to extreme prematurity, with a high risk of neonatal mortality and morbidity. Conversely, the prolongation of pregnancy with severe early onset preeclampsia may increase the risk of maternal morbidity, [2] [3] [4] [5] [6] [7] but may improve fetal prognosis. These conflicting interests between mother and fetus raise a dilemma in clinical decision making. This discussion is even more pressing as fetuses in early pre-eclampsia are also often severely growth restricted, further limiting their chances for (healthy) survival, both intrauterine and extrauterine, and increasing the risks of associated adverse long-term outcomes.
In 2006, Gaugler-Senden et al. 4 described high rates of major maternal complications (65%) and perinatal mortality (82%) after the expectant management of pregnancies complicated by severe, very early onset pre-eclampsia. In line with these findings, there is consensus that the prolongation of pregnancy should not be offered as a routine treatment option in women with severe pre-eclampsia with onset <24 weeks of gestation. [4] [5] [6] [7] [8] This subject is debated in the literature for a select group of patients, however, and this group is yet to be defined adequately. 9, 10 Neonatal care and resuscitation have improved, leading to a higher survival rate, 11 which may make management decisions even more difficult in the time frame at the limit of neonatal viability. Improved care and survival rates resulted in a new Dutch guideline regarding active neonatal resuscitation in spontaneously born premature neonates at a gestational age beyond 24 completed weeks in September 2010. 12 Before the introduction of the guideline, active neonatal resuscitation was not generally performed before 25 weeks of gestation, unless active resuscitation seemed justified. Expectant care for extreme early onset preeclampsia may seem defendable at an earlier gestational age in the hopes of neonatal survival. Iatrogenic prematurity in pre-eclampsia does not resemble spontaneous premature delivery, however.
In this nationwide case series we aimed to display the maternal and neonatal outcomes and prolongation of pregnancies with severe early onset pre-eclampsia and delivery before 26 weeks of gestation. Secondly, we analysed trends in management and maternal and neonatal outcomes over the years, and analysed the recurrence of pre-eclampsia in a subsequent pregnancy.
Methods

Study population
This study was performed in all ten tertiary care centres in the Netherlands. We included consecutive women who delivered between 22 and 26 weeks of gestation, between January 2008 and January 2014, and were diagnosed with severe pre-eclampsia. In each perinatal centre we identified women from electronic hospital health records and subsequently extracted data from their medical files. Women with a pregnancy complicated by fetal abnormalities or an intrauterine fetal death (IUFD) at admission were excluded. First-trimester ultrasound dating was standard practice for the determination of gestational age. The acknowledged ethical advisory board of the Academic Medical Centre, Amsterdam, approved the study (W13_106 # 13.17.0123).
Severe pre-eclampsia was defined as hypertension (diastolic blood pressure ≥110 mmHg or systolic blood pressure ≥160 mmHg on two occasions) in combination with proteinuria (defined as a protein/creatinine ratio of ≥30 mg/ mmol in a random sample or a urine protein excretion of ≥300 mg per 24 hours), with oliguria, cerebral or visual disturbances, pulmonary oedema, epigastric or upper-quadrant pain, impaired liver function, thrombocytopenia, after 20 weeks of gestation. 13 Chronic hypertension was defined as pre-existing hypertension or hypertension before 20 weeks of gestation. Superimposed pre-eclampsia includes new proteinuria or a sudden increase in proteinuria, if already present, in a woman with chronic hypertension. 13 HELLP syndrome was defined by haemolysis [elevated lactate dehydrogenase (LDH) levels ≥600 U/l], elevated liver enzymes [measured by levels of aspartate transaminase (ASAT) or alanine transferase (ALAT) ≥70 U/ l], and low platelets (<100 000/ml). 14 The deterioration of HELLP syndrome was defined as a new rise in laboratory findings after initial recovery. Small for gestational age (SGA) was defined as a birthweight below the fifth percentile.
After admission, women were stabilised by the administration of antihypertensive therapy, and in the case of severe hypertension by magnesium sulphate for the prevention of eclampsia. Fetal growth and condition was determined by ultrasound measurement and Doppler studies. Cardiotocography was performed when considered appropriate, depending on ultrasound findings and gestational age. The parents were then counselled by experienced obstetric and neonatology staff, and depending on the clinical condition of both mother and fetus, the obstetric management was determined. If active neonatal support was pursued, a course of 12 mg intramuscular betamethasone was given and repeated after 24 hours to accelerate fetal lung maturation. Initiating delivery, depending on maternal and fetal condition, was performed by induction of labour or caesarean section. Induction of labour was started in the case of good fetal condition (based on cardiotocography and ultrasound findings), or when the management was not aimed at the survival of the fetus (termination of pregnancy). A caesarean section was reserved for cases where it was considered to improve the chances of survival in compromised fetuses, or when normal delivery was not feasible (transverse position, maternal condition).
Neonates born before the implementation of the new Dutch guideline regarding active neonatal resuscitation, in 2010, 12 were in general not offered active support before 25 +0 weeks of gestation. After the new guideline, active support from a gestational age of 24 +0 weeks of gestation was optional, but could be refrained from in the case of poor fetal prognosis. The counselling of future parents on maternal and neonatal management was performed by gynaecologists and neonatologists. We will evaluate differences in prolongation before and after 2010, and trends in maternal and neonatal outcomes.
Maternal data included: maternal age at delivery; parity; medical and obstetric history; and cardiovascular risk factors, such as smoking, body mass index (BMI) before pregnancy, chronic hypertension diagnosed before pregnancy, and thrombophilia. We recorded pregnancy data (e.g. maximal blood pressures, proteinuria, maximal laboratory abnormalities, use of medication, HELLP syndrome at admission, mode of delivery, and complications). Maternal complications were defined as: HELLP syndrome (appearing or deteriorating after admission), eclampsia, pulmonary oedema (clinical and radiographic diagnosis), cerebrovascular incidents, hepatic capsular rupture, placental abruption, renal failure (with need for dialysis), and maternal death. We documented the interval between admission and delivery, and the indication for delivery. Neonatal data included: gestational age at birth, birthweight, sex, perinatal death, and complications. Neonatal complications if admitted to a Neonatal Intensive Care Unit (NICU) were defined as: intraventricular haemorrhage (IVH; defined as ≥grade 3, according to Papile et al. 15 ), retinopathy of prematurity (ROP; defined as ≥grade 3 in accordance with the International Classification for ROP 16 ), necrotising enterocolitis (NEC; defined as ≥stage 2 in accordance with the staging by Bell et al. If information on a subsequent pregnancy was available, these data were also documented.
Statistical analysis
Statistical analysis was performed using SPSS 23.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as means with standard deviations (SDs) or medians with interquartile ranges (IQRs).
Results
During the study period a total of 1 044 287 women delivered in the Netherlands, 114 868 of whom delivered in one of the ten tertiary care centres. During the study period, 133 women fulfilled the inclusion criteria, including eight multiple pregnancies, delivering 140 neonates. The incidence of severe premature pre-eclampsia between 22 and 26 weeks of gestation was 0.0127% nationally and 0.116% in the tertiary care setting. In one woman with a multiple pregnancy, an IUFD was discovered in one of the fetuses at 16 weeks of gestation, and was considered a singleton pregnancy in the neonatal analyses. Baseline characteristics are shown in Table 1 . Most women were nulliparous (64%). At admittance the median gestational age was 24 +0 weeks (IQR: 23 +1 -24 +5 weeks), and 61 women (46%) had a gestational age of less than 24 weeks. HELLP syndrome was present in 42 women (32%) at the time of admission.
An overview of management is shown in Figure 1 . After a median of 6 days from admittance, 22 (17%) intrauterine fetal deaths occurred, after which labour was induced. Delivery was indicated for maternal reasons in 85 women (64%) and for fetal indication in 26 women (20%). Maternal indication for delivery included the worsening of an existing maternal condition, based on: complications, deteriorating laboratory findings in HELLP syndrome, and uncontrollable blood pressures. Also, fetal condition played a role in the timing of delivery. Worsening fetal condition requiring immediate delivery or poor fetal prognosis encouraged more active management, whereas excellent fetal condition supported expectant management with fetal viability within reach. In 63 women this resulted in a termination of pregnancy and in 22 women active support was offered to the child(ren). In one case spontaneous preterm labour followed 5 days after admittance, which was classified as maternal indication. Table 2 shows outcomes of women and neonates. The median interval between admittance and delivery was 5 days (IQR: 3-9 days), with a range of 0-25 days. In 107 women (80%) this prolongation was more than 2 days. The median gestational age at delivery was 25 +0 weeks (IQR: 24 +2 -25 +4 weeks). Maternal complications occurred in 72 women (54%) and included: HELLP syndrome (new, deteriorating, or postpartum), eclampsia, lung oedema, placental abruption, hepatic capsular rupture, renal failure, and other (infection, cardiac decompensation, haemorrhagia postpartum). HELLP syndrome occurred in 83 women (62%). In 42 women (51%) HELLP was already present at the time of admittance, which deteriorated in 22 women (52%) during hospitalisation. In 38 women (46%) the HELLP syndrome appeared after admission. The appearance or deterioration of HELLP syndrome after admission (63 women) occurred after a median of 4 days from admittance, and in two women (2.4%) HELLP syndrome occurred postpartum. A completed course of betamethasone for fetal lung maturation was given in 52 women (58 neonates). An intended course could not be completed as a result of the deterioration of maternal or fetal condition in four women (7.7%). Active neonatal support was offered in 50 neonates (36%), 27 of whom (54%) survived (overall neonatal survival of was 19%). Only four (6.6%) neonates survived after admission before 24 weeks of gestation. Caesarean sections were performed in 48 women (36%); 24 caesarean sections (51%) were for fetal indication, after which 46 (96%) neonates were offered active support. Perinatal death occurred in 21 neonates (44%) after caesarean section.
Maternal and neonatal outcome
The incidence of neonatal complications in the 27 surviving children is also shown in Table 2 . Eighty-four percent of surviving neonates experience complications. Neonatal mortality was associated with NEC in five (19%), sepsis in 11 (41%), IVH in five (19%), and infant respiratory distress syndrome (IRDS) in five neonates (19%), mostly in combination. Other complications leading to neonatal death included: arrhythmia, intracardial thrombus, and multi-organ failure. Maternal and neonatal outcome in relation to gestational age at admittance is presented in Table S1 . From admission before 22 +6 weeks of gestation to admission between 25 and 26 weeks of gestation, the median interval between admittance and delivery ranged from 9.5 to 3.5 days, caesarean section rates ranged from 12 to 75%, and total perinatal death (with or without active support) ranged from 96 to 52%. Maternal complications ranged from 38 to 58%. Neonatal complications ranged from 80 to 100%.
Surviving neonates versus non surviving neonates
Gestational ages at delivery of the 27 pregnancies with surviving children were on average 7 days longer (24 +6 versus 23 +6 weeks of gestation; P < 0.001) than the non-surviving neonates (n = 106). Furthermore, the estimated fetal weight at admittance was higher (598 versus 454 g; P < 0.001), and children were less often SGA (30 versus 68%; P < 0.001) and less frequently presented abnormal umbilical artery Doppler flow (52 versus 78%; P = 0.011) than non-surviving neonates. Of the 27 surviving neonates, 26 were delivered by caesarean section. Neonatal sex did not affect survival (male, 37 versus 49%; P = 0.264). The clinical maternal syndrome was not significantly different regarding maximal blood pressures, maximal laboratory abnormalities, and medication.
Trends in prolongation
We investigated prolongation in more detail. Prolongation, presented as time between admittance and delivery in relation to gestational age at admittance, and survival of the neonate can be seen in Figure 2A . In the course of the study period the implementation of a new guideline for neonatal support allowed a shift in the minimal gestational age for active neonatal support from 25 +0 to 24 +0 weeks. 
Trends in maternal and neonatal outcome
Trends in maternal and neonatal outcomes over the course of the study period are shown in Figure S1 . The occurrence of maternal complications decreased from 65-75 to 41% during the study period, and neonatal survival after active neonatal support fluctuated between 40 and 80%. Most surviving neonates (21 of 27) were born between 25 and 26 weeks of gestation. Only six neonates born between 24 and 25 weeks of gestation (after 2010) survived. The caesarean section rate peaked at 62% in 2011, whereas it ranges from 26 to 38% in the remaining years of the study period. Only one caesarean section (8.3%) was performed at a gestational age before 24 weeks (2013). In women with a gestation before 25 weeks (n = 41), nine caesarean sections (22%) were performed.
Subsequent pregnancies
Forty-two women (32%) of the 133 women were lost to follow-up and information on subsequent pregnancies could not be obtained. A subsequent pregnancy occurred in 61 women (67%), two of whom miscarried. We had complete data of 55 continuing pregnancies. They delivered again after a mean of 20 months (SD: 10 months) after the index delivery, at a mean gestational age of 35 +4 weeks (SD: 36 days).
Of the 55 subsequent pregnancies, 17 women (31%) had recurrent pre-eclampsia at a mean gestational age 32 +6 weeks (SD: 38 days), of which three pregnancies were complicated by HELLP (18%). Four women (7.3%) delivered again before 28 weeks of gestation. Perinatal death occurred in five subsequent pregnancies (9.6%): two pregnancies were terminated (trisomy 18 and fetal intracerebral haemorrhage), in two other pregnancies IUFD occurred, and one neonatal death was associated with severe growth restriction. Eventually, 50 women (91%) had a living child from the subsequent pregnancy.
Discussion
Main findings
In the Netherlands, women with severe early onset preeclampsia are delivered mostly for maternal reasons after a median prolongation of 5 days, which was unaffected by the implementation of the new guideline for active neonatal support. Maternal complications occurred frequently (54%) and neonatal survival was limited (19%), and troubled by complications (85%). The recurrence rate of preeclampsia was 31%; however, at significant later gestational age (mean: 32 +6 weeks of gestation) with 91% neonatal survival.
Strengths and limitations
This contemporary case series is unique, as all Dutch perinatal centres participated in this study, and we were therefore able to include all women who met the inclusion criteria. Data collection was complete because we collected information from the medical files.
Baseline characteristics show serious illness of the mother and compromised fetal condition, as expected. New development or deterioration of HELLP syndrome (63 women) contributed to the maternal reason to deliver after expectant management. With this study we are unable to answer the question of whether HELLP syndrome or a deterioration of HELLP syndrome could have been prevented by prompt delivery.
There are several sources of potential bias that hinder the drawing of too firm conclusions. First, the size of the study is rather small, in line with the rarity of this extreme condition and similar, even smaller, published cohorts. [4] [5] [6] [7] Furthermore, the retrospective nature of this case series and the fact that we were unable to retrieve the reasons behind the different management regimes do not allow for a meaningful comparison of outcomes between groups of expectant care or immediate delivery. Finally, women were selected for gestational age at delivery rather than gestational age at decision for management regime, inducing an information gap for women who are admitted before, but delivered after 26 weeks of gestation.
Interpretation
The overall maternal complication rate of 68% (including HELLP syndrome at admittance) is comparable with rates reported in the literature. [4] [5] [6] [7] In contrast to other literature, our study presents the appearance of or deterioration of HELLP syndrome after admittance, which can be regarded as a complication of expectant management. Although a decreasing trend may be seen in the occurrence of maternal complications over the study period, it is too soon to draw any conclusions about the reasons for this decrease. Perinatal mortality and neonatal complications are also comparable with the literature on severe early onset preeclampsia; [4] [5] [6] [7] however, compared with perinatal death rates of 45% in extremely premature neonates in a Swedish nationwide cohort without maternal pre-eclampsia, 11 the rate of perinatal death was much higher in our study. This concurs with the concept that neonates born from mothers with severe early onset pre-eclampsia are not comparable with spontaneous prematurely born children. On the other hand, the neonatal survival rate after active support (27/50, 54%) is comparable with the results of the Swedish study.
11
Neonatal survival after extreme premature pre-eclampsia in this case series does not seem to have improved over recent years. From 2010 active support has been offered at an earlier gestational age, which may have effected survival rates.
In 80% of the women included in this study, the prolongation was 3 days or more, despite the high maternal complication rate and perinatal mortality. The prolongation time between admittance and delivery was in general 5 days, which is comparable with the results of some studies. 5, 6 Prolongation may be longer if we had been able to include women that delivered beyond 26 weeks of gestation. In other studies much longer prolongation times of up to 32 days have been reported. 4, 7, 10 In contrast to our case series, only women eligible for expectant care were selected in these studies. As can be seen in Table S1 and Figure 2A , survival is very limited when presenting before 24 weeks of gestation, despite prolongation. Ganzevoort and Sibai have both reviewed different management regimes described in the literature. 8, 10 They conclude that before 24 weeks of gestation, because of the absence of perinatal benefits and high maternal complication rate, an expectant management approach should not be offered routinely. Our findings endorse this consensus. Prolongation should only be offered to a select group of women (that still needs to be defined), in whom it is believed to benefit the neonatal prognosis, preferably after 24 weeks of gestation at presentation. In our study, maternal complications, perinatal death, and neonatal complications after 24 weeks of gestation were still very high, and in 85 women (64%) active neonatal support was never offered (59 neonates) despite prolongation, as their fetus was not considered viable. In line with other studies, this study did not provide the selection criteria for women considered eligible for expectant care. The differences presented between pregnancies with and without surviving neonates could give guidance for counselling on this matter.
Although we must keep in mind that because of the rareness of this clinical dilemma the number of patients does not warrant making too firm conclusions, trend analyses show a peak caesarean section rate in 2011. These findings could suggest a subtle influence of this guideline, with presumed improved neonatal survival chances after 25 weeks of gestation and after caesarean section.
In general, women need to be counselled carefully, weighing the risk for maternal complications against high perinatal mortality.
Conclusion
Severe pre-eclampsia at extreme premature gestational age is a rare but serious condition with high rates of maternal and neonatal complications and perinatal death. Prolongation of more than 2 days was often applied in the Netherlands, despite the consensus in international literature that prolongation of pregnancy should not be offered as a routine treatment option. Prolongation does not necessarily lead to fetal viability. Considering the limits of prolongation, women need to be counselled carefully, weighing the high risk for maternal complications against limited neonatal survival and/or extreme prematurity, and its sequelae. Estimated fetal weight, growth restriction, and Doppler abnormalities should be taken into account. Furthermore, we should also provide information on the positive prospects regarding maternal and neonatal outcome in a future pregnancy.
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